1H NMR-based metabolomics study on a goldfish model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)

Chemico-Biological Interactions

Volumn 223, Issue , 2014, Pages 18-26

  Lu, Zhaoguang ^a   Wang, Junsong ^b   Li, Minghui ^a   Liu, Qingwang ^a   Wei, Dandan ^a   Yang, Minghua ^a   Kong, Lingyi ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b NANJING UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

1H NMR; Goldfish; Metabolomics; MPTP; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3 HEXENEDIOATE; 3,4 DIHYDROXYPHENYLACETIC ACID; ACETANILIDE; ALANINE; ALANYLALANINE; ALCOHOL; AMINO ACID; ARACHIC ALCOHOL; BETAINE; CHOLESTEROL; CREATINE PHOSPHATE; CREATININE; DOPAMINE; FATTY ACID; GLUTAMINE; INOSITOL; ISOCITRIC ACID; ISOLEUCINE; LEUCINE; MALONIC ACID; N ACETYLASPARTIC ACID; OMEGA 3 FATTY ACID; PHOSPHATIDYLCHOLINE; PHOSPHORYLCHOLINE; POLYUNSATURATED FATTY ACID; SCYLLO INOSITOL; TAURINE; UNCLASSIFIED DRUG; VALINE;

AMINO ACID BRAIN LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISCRIMINANT ANALYSIS; DOPAMINE BRAIN LEVEL; GOLDFISH; LIPID BRAIN LEVEL; METABOLITE; METABOLOMICS; MOLECULAR PATHOLOGY; NERVE CELL LESION; NERVE CELL NECROSIS; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PARTIAL LEAST SQUARES DISCRIMINANT ANALYSIS; PROTON NUCLEAR MAGNETIC RESONANCE; SPECTROSCOPY; TWO DIMENSIONAL STATISTICAL TOTAL CORRELATION SPECTROSCOPY; ANIMAL; ANIMAL BEHAVIOR; BRAIN; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; HUMAN; INTOXICATION; LIPID METABOLISM; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOPHYSIOLOGY; SWIMMING;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; 3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; BEHAVIOR, ANIMAL; BRAIN; DISEASE MODELS, ANIMAL; DOPAMINE; GOLDFISH; HUMANS; LIPID METABOLISM; MAGNETIC RESONANCE SPECTROSCOPY; METABOLOMICS; MPTP POISONING; PARKINSON DISEASE; SWIMMING;

EID: 84907942128     PISSN: 00092797     EISSN: 18727786     Source Type: Journal    
DOI: 10.1016/j.cbi.2014.09.006     Document Type: Article

References (53)

1. C. Chassain, G. Bielicki, E. Durand, S. Lolignier, F. Essafi, A. Traore, and F. Durif Metabolic changes detected by proton magnetic resonance spectroscopy in vivo and in vitro in a murin model of Parkinson's disease, the MPTP-intoxicated mouse J. Neurochem. 105 2008 874 882
2. E. Masliah, E. Rockenstein, I. Veinbergs, Y. Sagara, M. Mallory, M. Hashimoto, and L. Mucke β-Amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease Proc. Natl. Acad. Sci. U.S.A. 98 2001 12245 12250
3. R.S. Burns, C.C. Chiueh, S.P. Markey, M.H. Ebert, D.M. Jacobowitz, and I.J. Kopin A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine Proc. Natl. Acad. Sci. U.S.A. 80 1983 4546 4550
4. R.E. Heikkila, A. Hess, and R.C. Duvoisin Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1, 2, 5, 6-tetrahydropyridine in mice Science 224 1984 1451 1453
5. C.S. Lam, V. Korzh, and U. Strahle Zebrafish embryos are susceptible to the dopaminergic neurotoxin MPTP Eur. J. Neurosci. 21 2005 1758 1762
6. H. Matsui, Y. Taniguchi, H. Inoue, K. Uemura, S. Takeda, and R. Takahashi A chemical neurotoxin, MPTP induces Parkinson's disease like phenotype, movement disorders and persistent loss of dopamine neurons in medaka fish Neurosci. Res. 65 2009 263 271
7. A.H. Schapira Mitochondria in the aetiology and pathogenesis of Parkinson's disease Lancet Neurol. 7 2008 97 109
8. O. Weinreb, and M.B. Youdim A model of MPTP-induced Parkinson's disease in the goldfish Nat. Protoc. 2 2007 3016 3021
9. H.B. Pollard, G.A. Kuijpers, O.M. Adeyemo, M.B. Youdim, and G. Goping The MPTP-induced parkinsonian syndrome in the goldfish is associated with major cell destruction in the forebrain and subtle changes in the optic tectum Exp. Neurol. 142 1996 170 178
10. G. Goping, H.B. Pollard, O.M. Adeyemo, and G.A. Kuijpers Effect of MPTP on dopaminergic neurons in the goldfish brain: a light and electron microscope study Brain Res. 687 1995 35 52
11. A. Poli, T. Guarnieri, F. Facchinetti, and L. Villani Effect of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) in goldfish brain Brain Res. 534 1990 45 50
12. R. Kaddurah-Daouk, and K.R.R. Krishnan Metabolomics: a global biochemical approach to the study of central nervous system diseases Neuropsychopharmacology 34 2008 173 186
13. N.J. Serkova, T.J. Standiford, and K.A. Stringer The emerging field of quantitative blood metabolomics for biomarker discovery in critical illnesses Am. J. Respir. Crit. Care 184 2011 647
14. 1H NMR metabolomics approach J. Pharm. Biomed. Anal. 88 2014 106 116
15. H. Pollard, K. Dhariwal, O. Adeyemo, C. Markey, H. Caohuy, M. Levine, S. Markey, and M. Youdim A parkinsonian syndrome induced in the goldfish by the neurotoxin MPTP FASEB J. 6 1992 3108 3116
16. O. Beckonert, H.C. Keun, T.M. Ebbels, J. Bundy, E. Holmes, J.C. Lindon, and J.K. Nicholson Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts Nat. Protoc. 2 2007 2692 2703
17. S. Pain, A. Gochard, S. Bodard, Z. Gulhan, C. Prunier-Aesch, and S. Chalon Toxicity of MPTP on neurotransmission in three mouse models of Parkinson's disease Exp. Toxicol. Pathol. 65 2013 689 694
18. J. Nellore, C. Pauline, and K. Amarnath Bacopa monnieri phytochemicals mediated synthesis of platinum nanoparticles and its neurorescue effect on 1-methyl 4-phenyl 1,2,3,6 tetrahydropyridine-induced experimental Parkinsonism in zebrafish J. Neurodegener. Dis. 2013 2013
19. J. Araya, R. Rodrigo, L.A. Videla, L. Thielemann, M. Orellana, P. Pettinelli, and J. Poniachik Increase in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease Clin. Sci. 106 2004 635 643
20. B. Ross, A. Moszczynska, J. Erlich, and S. Kish Low activity of key phospholipid catabolic and anabolic enzymes in human substantia nigra: possible implications for Parkinson's disease Neuroscience 83 1998 791 798
21. M. Bousquet, M. Saint-Pierre, C. Julien, N. Salem, F. Cicchetti, and F. Calon Beneficial effects of dietary omega-3 polyunsaturated fatty acid on toxin-induced neuronal degeneration in an animal model of Parkinson's disease FASEB J. 22 2008 1213 1225
22. L.M. de Lau, P.J. Koudstaal, A. Hofman, and M.M. Breteler Serum cholesterol levels and the risk of Parkinson's disease Am. J. Epidemiol. 164 2006 998 1002
23. I. Björkhem, and S. Meaney Brain cholesterol: long secret life behind a barrier Arterioscler. Thromb. Vasc. Biol. 24 2004 806 815
24. J.E. Vance Dysregulation of cholesterol balance in the brain: contribution to neurodegenerative diseases Dis. Model. Mech. 5 2012 746 755
25. J.-P. Liu, Y. Tang, S. Zhou, B.H. Toh, C. McLean, and H. Li Cholesterol involvement in the pathogenesis of neurodegenerative diseases Mol. Cell. Neurosci. 43 2010 33 42
26. R. Seet, C.-Y.J. Lee, E.C. Lim, J.J. Tan, A.M. Quek, W.-L. Chong, W.-F. Looi, S.-H. Huang, H. Wang, and Y.-H. Chan Oxidative damage in Parkinson disease: measurement using accurate biomarkers Free Radic. Biol. Med. 48 2010 560 566
27. R. Musanti, E. Parati, E. Lamperti, and G. Ghiselli Decreased cholesterol biosynthesis in fibroblasts from patients with Parkinson disease Biochem. Med. Metab. Biol. 49 1993 133 142
28. C. Smith, J.M. Carney, P. Starke-Reed, C. Oliver, E. Stadtman, R. Floyd, and W. Markesbery Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease Proc. Natl. Acad. Sci. U.S.A. 88 1991 10540 10543
29. J. Urenjak, S.R. Williams, D.G. Gadian, and M. Noble Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types J. Neurosci. 13 1993 981 989
30. M. Firbank, R. Harrison, and J. O'Brien A comprehensive review of proton magnetic resonance spectroscopy studies in dementia and Parkinson's disease Dement. Geriatr. Cogn. Disord. 14 2002 64 76
31. E. O'Gorman, G. Beutner, T. Wallimann, and D. Brdiczka Differential effects of creatine depletion on the regulation of enzyme activities and on creatine-stimulated mitochondrial respiration in skeletal muscle, heart, and brain Biochim. Biophys. Acta 1276 1996 161 170
32. 31P NMR study Biochem. Biophys. Res. Commun. 225 1996 819 825
33. R.T. Matthews, R.J. Ferrante, P. Klivenyi, L. Yang, A.M. Klein, G. Mueller, R. Kaddurah-Daouk, and M.F. Beal Creatine and cyclocreatine attenuate MPTP neurotoxicity Exp. Neurol. 157 1999 142 149
34. M. Tokarska-Schlattner, R.F. Epand, F. Meiler, G. Zandomeneghi, D. Neumann, H.R. Widmer, B.H. Meier, R.M. Epand, V. Saks, and T. Wallimann Phosphocreatine interacts with phospholipids, affects membrane properties and exerts membrane-protective effects PLoS One 7 2012 e43178
35. 31P MRS of PCA extracts of postmortem Alzheimer's disease brain Neurobiol. Aging 17 1996 349 357
36. R.M. Salek, R.E. Colebrooke, R. Macintosh, P.J. Lynch, B.C. Sweatman, P.C. Emson, and J.L. Griffin A metabolomic study of brain tissues from aged mice with low expression of the vesicular monoamine transporter 2 (VMAT2) gene Neurochem. Res. 33 2008 292 300
37. S.A. Farber, B.E. Slack, and J.K. Blusztajn Acceleration of phosphatidylcholine synthesis and breakdown by inhibitors of mitochondrial function in neuronal cells: a model of the membrane defect of Alzheimer's disease FASEB J. 14 2000 2198 2206
38. P.A. LeWitt, J. Li, M. Lu, T.G. Beach, C.H. Adler, and L. Guo 3-hydroxykynurenine and other Parkinson's disease biomarkers discovered by metabolomic analysis Mov. Disord. 28 2013 1653 1660
39. P. LeWitt Recent advances in CSF biomarkers for Parkinson's disease Parkinsonism Relat. Disord. 18 2012 S49 S51
40. M. Alirezaei, G. Jelodar, P. Niknam, Z. Ghayemi, and S. Nazifi Betaine prevents ethanol-induced oxidative stress and reduces total homocysteine in the rat cerebellum J. Physiol. Biochem. 67 2011 605 612
41. G. Kanbak, O.C. Arslan, A. Dokumacioglu, K. Kartkaya, and M.E. ̄nal Effects of chronic ethanol consumption on brain synaptosomes and protective role of betaine Neurochem. Res. 33 2008 539 544
42. D. Religa, K. Czyzewski, M. Styczynska, B. Peplonska, J. Lokk, M. Chodakowska-Zebrowska, K. Stepien, B. Winblad, and M. Barcikowska Hyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in patients with Parkinson's disease Neurosci. Lett. 404 2006 56 60
43. K.K. Kharbanda, D.D. Rogers, M.E. Mailliard, G.L. Siford, A.J. Barak, H.C. Beckenhauer, M.F. Sorrell, and D.J. Tuma A comparison of the effects of betaine and S-adenosylmethionine on ethanol-induced changes in methionine metabolism and steatosis in rat hepatocytes J. Nutr. 135 2005 519 524
44. R.A. Kauppinen, and S.R. Williams Nuclear magnetic resonance spectroscopy studies of the brain Prog. Neurobiol. 44 1994 87 118
45. V. Govindaraju, K. Young, and A.A. Maudsley Proton NMR chemical shifts and coupling constants for brain metabolites NMR Biomed. 13 2000 129 153
46. T. Tsang, J. Haselden, and E. Holmes Metabonomic characterization of the 3-nitropropionic acid rat model of Huntington's disease Neurochem. Res. 34 2009 1261 1271
47. 1H MRS in the evaluation of Huntington's and Parkinson's diseases Neurology 50 1998 1033 1040
48. J. Prestel, K. Gempel, T.-K. Hauser, K. Schweitzer, H. Prokisch, U. Ahting, D. Freudenstein, E. Bueltmann, T. Naegele, and D. Berg Clinical and molecular characterisation of a Parkinson family with a novel PINK1 mutation J. Neurol. 255 2008
49. S. Ahmed, W. Santosh, S. Kumar, and H. Christlet Metabolic profiling of Parkinson's disease: evidence of biomarker from gene expression analysis and rapid neural network detection J. Biomed. Sci. 16 2009 63
50. A. Brand, C. Richter-Landsberg, and D. Leibfritz Multinuclear NMR studies on the energy metabolism of glial and neuronal cells Dev. Neurosci. 15 1993 289 298
51. J. Busciglio, and B.A. Yankner Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro Nature 378 1995 776 779
52. F. Beacher, A. Simmons, E. Daly, V. Prasher, C. Adams, M.L. Margallo-Lana, R. Morris, S. Lovestone, K. Murphy, and D.G. Murphy Hippocampal myo-inositol and cognitive ability in adults with Down syndrome: an in vivo proton magnetic resonance spectroscopy study Arch. Gen. Psychiatry 62 2005 1360
53. J. McLaurin, M.E. Kierstead, M.E. Brown, C.A. Hawkes, M.H. Lambermon, A.L. Phinney, A.A. Darabie, J.E. Cousins, J.E. French, and M.F. Lan Cyclohexanehexol inhibitors of Aβ aggregation prevent and reverse Alzheimer phenotype in a mouse model Nat. Med. 12 2006 801 808